Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Focus on call on NASH is unfortunate

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Jul 15, 2021 10:35am

100 Views

Post# 33548962

RE:RE:Focus on call on NASH is unfortunate

I think listening to the call will give you a better understanding,,,,,

qwerty22 wrote:
I haven't listened to the call yet but that's understandable. This is a U-turn. The path to Ph3 has evaporated. I think it's clear now but I still think the company are being opaque, they should tell the story straight then they wouldn't get the Qs.

SPCEO1 wrote: Understandable perhaps, but still unfortunate.